SCHEMBL6930848

SCHEMBL6930848

CC(C)Oc1ccc(OC(C)C)c(C=O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 1/20 0.53
ERN1 O75460 2/20 0.49
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
KDM4E B2RXH2 2/20 0.42
RAB9A P51151 1/20 0.42
PARP10 Q53GL7 1/20 0.42
BRD4 O60885 1/20 0.41
BRPF1 P55201 1/20 0.41
TUBB1 Q9H4B7 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
JUN P05412 1/20 0.40
NFKB1 P19838 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27945949 0.89 ALDH1A1 (0.56) ALDH1A3ERN1ALDH1A1CYP1A2MAPT
SCHEMBL12540995 0.85 ALDH1A1 (0.55) ALDH1A3ERN1ALDH1A1KMT2ACYP1A2
SCHEMBL24530453 0.85 ALDH1A3 (0.57) ALDH1A3ERN1ALDH1A1KMT2AKDM4E
SCHEMBL4939627 0.84 ALDH1A3 (0.41) ALDH1A3ERN1ALDH1A1CYP1A2MAPT
SCHEMBL19564845 0.84 ERN1 (0.43) ALDH1A3ERN1ALDH1A1KMT2ACYP1A2
SCHEMBL41984 0.84 ALDH1A1 (0.46) ALDH1A3ERN1ALDH1A1KMT2ACYP1A2
SCHEMBL6935704 0.81 ALDH1A1 (0.41) ALDH1A3ERN1ALDH1A1KMT2AMAPT
SCHEMBL177142 0.80 ALDH1A1 (0.52) ALDH1A3ERN1ALDH1A1KMT2ACYP1A2
SCHEMBL21558730 0.80 ERN1 (0.47) ALDH1A3ERN1ALDH1A1CYP1A2MAPT
SCHEMBL22272205 0.80 MAPT (0.41) ALDH1A3ERN1ALDH1A1CYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1371657-A1 Transition-metal complexes and use thereof in transition-metal catalysed reactions.. Bayer Aktiengesellschaft (DE) 2003-12-17 EP disclosed
US-20030220512-A1 Novel transition metal complexes and their use in transition metal-catalysed reactions BAYER AKTIENGESELLSCHAFT (DE) 2003-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220512-A1 Novel transition metal complexes and their use in transition metal-catalysed reactions AP1M1, AP3M1, CYC1 ALDH1A3 3225/4885ERN1 1660/4885ALDH1A1 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.